Search
Radotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
BL-1020
go.drugbank.com/drugs/DB05687InvestigationalBL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
TST10088
go.drugbank.com/drugs/DB05151ExperimentalThese molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis. … TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998]
Synonyms: Copper bis(histidinate)Gadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigational[A263156] Gadoxetate is a unique gadolinium-based contrasting agent (GBCA) with both dynamic phase and hepatobiliary phase and thus has different pharmacokinetic and pharmacodynamic properties compared
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to
Plazinemdor
go.drugbank.com/drugs/DB21493InvestigationalPlazinemdor has a monoisotopic molecular weight of 432.12 Da.
Tirfipiravir
go.drugbank.com/drugs/DB21648ExperimentalTirfipiravir has a monoisotopic molecular weight of 355.1 Da.
Tubercidin
go.drugbank.com/drugs/DB03172ExperimentalAn antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids
Clometherone
go.drugbank.com/drugs/DB19465ExperimentalClometherone has a monoisotopic molecular weight of 362.2 Da.